DOTA-LM3 (TFA)

DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo (D-Cys-Tyr-D-4-amino-Phe (carbamoyl) -Lys-Thr-Cys) D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis[1][2]. DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

C71H94ClF3N16O21S2

1664.18

O=C([C@@H](NC([C@@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@@H](C(N)=O)CC2=CC=C(C=C2)O)=O)NC([C@@H](NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC4=CC=C(C=C4)Cl)=O)=O)CC5=CC=C(C=C5)O)N[C@@H]1CC6=CC=C(C=C6)NC(N)=O.OC(C(F)(F)F)=O

Radionuclide-Drug Conjugates (RDCs) ; Somatostatin Receptor

RDC Peptide

99.3

H2O : 100 mg/mL (ultrasonic)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

Blue Ice